BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35701319)

  • 1. Application of histology-agnostic treatments in metastatic colorectal cancer.
    Sartore-Bianchi A; Agostara AG; Patelli G; Mauri G; Pizzutilo EG; Siena S
    Dig Liver Dis; 2022 Oct; 54(10):1291-1303. PubMed ID: 35701319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
    Vranic S; Basu GD; Hall DW; Gatalica Z
    Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic landscape and future direction of metastatic colorectal cancer.
    Bando H; Ohtsu A; Yoshino T
    Nat Rev Gastroenterol Hepatol; 2023 May; 20(5):306-322. PubMed ID: 36670267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
    Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. If it's a target, it's a pan-cancer target: Tissue is not the issue.
    Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
    Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Profiling in Metastatic Colorectal Cancer.
    Armstrong SA; Malley R; Weinberg BA
    Oncology (Williston Park); 2020 Sep; 34(9):352-355. PubMed ID: 32965665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report.
    Gallois C; Taieb J; Sabouret A; Broudin C; Karoui M; Garinet S; Zaanan A
    Genes Chromosomes Cancer; 2022 Feb; 61(2):114-118. PubMed ID: 34773327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.
    Tateo V; Marchese PV; Mollica V; Massari F; Kurzrock R; Adashek JJ
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis.
    Nunes L; Aasebø K; Mathot L; Ljungström V; Edqvist PH; Sundström M; Dragomir A; Pfeiffer P; Ameur A; Ponten F; Mezheyeuski A; Sorbye H; Sjöblom T; Glimelius B
    Acta Oncol; 2020 Apr; 59(4):417-426. PubMed ID: 31924107
    [No Abstract]   [Full Text] [Related]  

  • 13. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current Status and Challenges in Tumor Agnostic Treatment].
    Komine K
    Gan To Kagaku Ryoho; 2023 Jun; 50(6):657-661. PubMed ID: 37317595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients.
    Aasebø KØ; Dragomir A; Sundström M; Mezheyeuski A; Edqvist PH; Eide GE; Ponten F; Pfeiffer P; Glimelius B; Sorbye H
    Cancer Med; 2019 Jul; 8(7):3623-3635. PubMed ID: 31070306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Analysis of Treatment Pathways in Patients With BRAF
    Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
    Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.